Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.
“The AAPI is an impressive organization that fosters the continued leadership of healthcare professionals of Indian origin through educational and networking opportunities, while also supporting the next generation of leaders and giving back to people in need through its charitable foundation,” said Dr. Musunuri. “We look forward to interacting with top physicians, health professionals, academicians, and scientists from across the country to drive positive change throughout our dynamic healthcare environment.”
“It’s an honor to share more about Ocugen’s scientific platforms, especially modifier gene therapy, with this important audience,” said Dr. Upadhyay. “Opportunities like this for an open dialogue among industry and practitioners is critical to advancing treatment options and providing access for patients.”
Details on Dr. Upadhyay’s participation are as follows:
Product Theater: “Emerging Cell and Gene Therapy Technologies: Novel curative approaches to breaking barriers in disease management”
Date: Friday, July 7, 2023
Time: 8:50 – 9:10 a.m. ET
Location: Philadelphia Marriott Downtown, Philadelphia, PA – 5th Floor – Salon BCD
Details on Dr. Musunuri’s participation are as follows:
CEO Leaders Forum: “Shaping Healthcare for the Future”
Date: Saturday, July 8, 2023
Time: 3 – 4:15 p.m. ET
Location: Philadelphia Marriott Downtown, Philadelphia, PA – Rooms 302-306
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Head of Communications